S&P 5007,765.36▼0.5% Nasdaq27,193.34▼1.2% Dow51,231.64▲0.1% Russell 2K2,794.13▲0.0% 10-Yr5.23%−5bp VIX15.41+0.33 WTI$91.10▲3.2% Gold$4,157.80▲0.4% EUR/USD1.122▼0.3% BTC$82,825▲1.2% Nikkei70,036▼0.9%
At close · Thu, Oct 8, 2026
Daily Market Updates.

US Markets

Home›US Markets›Equities›Novo's next-generation obesity drug shows 25% weight l…

Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis

Reported · Written up by our desk · Equities

Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy.

← Newer storyEternal share: What to expect from Zomato parent’s Q2 results 2026 as…

More like this

US MarketsAudit regulator looking into Manchester City accounting
US MarketsBritain Is Said to Approve New Gas Drilling in the North Sea
US MarketsSpaceX Swings to a Profit, Even as A.I. Spending Soars
US MarketsNetflix posts third-quarter earnings beat, but shares fall on advertising and revenue guidance
US MarketsThe Social Security Administration corrected millions of records, and says there’s more to fix

Sources

CNBC MarketsNovo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis
CNBC WorldNovo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.